I. COMMENCED TRADING IN OCTOBER

INITIAL OFFERINGS

Company
(Symbol)#

Date Filed

Date Comm.

Shares/ Units (M)

Price

Shares
Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)


There were no initial public offerings in October.

Total: $0M

Number of IPOs in October: 0

Average value of October IPOs: $0M

Number of IPOs for 2001: 7

Total raised in IPOs in 2001: $207.05M

Average value of IPOs in 2001: $29.58M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date Filed

Date Comm.

Shares/ Units (M)

Price

Shares
Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)


BioMS Medical
Corp.
(Canada;
CDNX:MS)1

10/23

10/23

3.3U

C$2.50

ND

Yorkton Securities Inc.

C$8.25 (US
$5.24)

ND

Isis Pharma-
ceuticals Inc.
(ISIP)2

10/9

10/23

5.75S

$20

52.1

UBS Warburg LLC; Robertson Stephens Inc.; Needham & Co. Inc.; Fortis Securities Inc.

$115

$107.8

Sicor Inc.
(SCRI)3

10/11

10/11

10S

$18.50

110.7

Merrill Lynch & Co.; CIBC World Markets Corp.; SG Cowen Securities Corp.

$185

$175.9

EXERCISED OVERALLOTMENT OPTIONS

Telik Inc.
(TELK)4

8/20

10/18

0.6S

$6.50

26.9

Lehman Brothers Inc.; Legg Mason Wood Walker; UBS Warburg LLC; Lazard Freres & Co. LLC; Needham & Co. Inc.

$3.9

$3.7

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; CDNX = Canadian Venture Exchange; ND = Not disclosed

1 BioMS issued 3.3M units, each consisting of one common share and one-half of a purchase warrant. A full warrant entitles the holder to purchase one common share at C$5.80 each until Oct. 22, 2003.

2 Isis' offering includes the full exercise of the underwriters' overallotment option for 750,000 shares.

3 Sicor's offering was for 20M shares, 10M sold by the company and 10M sold by stockholder Rakepoll Finance, for total gross proceeds of $370M. Underwriters have an option to purchase 3M shares to cover overallotments.

4 Telik's underwriters exercised their overallotment option to purchase an additional 600,000 shares. The offering was completed in September.

Total: $305.24M

Number of follow-on offerings in October: 3

Average value of October follow-ons: $101.7

Number of follow-on offerings in 2001: 31

Total raised in follow-ons in 2001: $2,478.71M

Average value of follow-ons in 2001: $79.6M

II. FILED AND PENDING

INITIAL OFFERINGS

Company
(Symbol/
Proposed
Symbol)#*

Date Filed

Shares/ Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)


AgraQuest
Inc.
(AGRQ)1

8/3

N/A

N/A

N/A

Merrill Lynch & Co.; Stephens Inc.; First Union Securities Inc.

$75

APBiotech
(APBI; unit
of Nycomed
Amersham plc)2

10/3/00

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead); Goldman, Sachs & Co. (co-lead); Chase H&Q; Salomon Smith Barney

$291.2

BioNumerik
Pharmaceu-
ticals Inc.
(BNPI)3

3/2

N/A

N/A

N/A

Morgan Stanley Dean Witter; UBS Warburg LLC; SG Cowen Securities Corp.

$50

CombiMatrix
Corp.
(CLMX)4

11/22

N/A

N/A

N/A

Salomon Smith Barney (co-lead); JP Morgan & Co. (co-lead)

$100

diaDexus Inc.
(DDXS)5

11/20

7S

$12-14

31.1

Lehman Brothers Inc.; CIBC World Markets Corp.; Robertson Stephens Inc.; Fidelity Capital Markets

$91

Northwest
Biothera-
peutics Inc.
(NWBT)6

8/13

3.5S

$9-$11

16.5

C.E. Unterberg, Towbin

$35

Ribapharm
Inc.
(RIBA)7

5/15

18S

$13-15

N/A

UBS Warburg LLC; CIBC World Markets Corp.

$252

Xcyte
Therapies
Inc.
(XCYT)8

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead); U.S. Bancorp Piper Jaffray (co-lead); Dain Rauscher Inc.; First Security Van Kasper Inc.

$86.2

ZymoGenetics
Inc.
(ZGEN)9

9/10

N/A

N/A

N/A

Lehman Brothers Inc. (co-lead); Merrill Lynch & Co. (co-lead); Bear, Stearns & Co. Inc.; Pacific Growth Equities Inc.

$180

FOLLOW-ON OFFERINGS

Ariad Pharma-
ceuticals Inc.
(ARIA)10

6/22

4.5S

$4.79

34.6

N/A

$21.6

Cell Pathways
Inc.
(CLPA)11

2/7

N/A

N/A

N/A

N/A

$25

Cerus Corp.
(CERS)12

8/13

N/A

N/A

15.7

N/A

$300

CollaGenex
Pharmaceu-
ticals Inc.
(CGPI)13

10/26

0.965S

$8.01

N/A

N/A

$7.7

Cytogen Corp.
(CYTO)14

10/26

10S

$2.50

78.9

N/A

$25

Exelixis Inc.
(EXEL)15

7/30

N/A

N/A

49.2

N/A

$150

Genaissance
Pharmaceu-
ticals Inc.
(GNSC)16

10/18

N/A

N/A

22.8

N/A

$35

ICOS Corp.
(ICOS)17

6/26

N/A

N/A

53

N/A

$300

InSite
Vision Inc.
(AMEX:ISV)18

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co. (placement agent)

$40

Labopharm
Inc.
(Canada;
TSE:DDS)19

10/29

5.2S

C$6.75

N/A

Research Capital Corp.; CIBC World Markets Corp.; National Bank Financial Inc.; TC Securities Inc.

C$35.1 (US
$22)

Matrix Pharm-
aceuticals Inc.
(MATX)20

5/25

N/A

N/A

26

N/A

$30

Microcide
Pharma-
ceuticals Inc.
(MCDE)21

2/12

N/A

N/A

N/A

N/A

$35

Neo-
Therapeutics
Inc.
(NEOT)22

1/3

N/A

N/A

21.9

N/A

$50

Tularik Inc.
(TLRK)23

8/14

N/A

N/A

49.2

N/A

$250

Valentis Inc.
(VLTS)24

9/27

N/A

N/A

29.9

N/A

$45

ViroPharma
Inc.
(VPHM)25

7/3

N/A

N/A

18.7

N/A

$300

Vysis Inc.
(VYSI)26

8/8

1S

$25.96

11.2

UBS Warburg LLC; First Union Securities Inc.; Pacific Growth Equities Inc.

$26

III. WITHDRAWN AND POSTPONED

INITIAL OFFERINGS

Company
(Symbol/
Proposed
Symbol)#*

Date Filed/ Date Pulled

Shares/ Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)


Cellomics
Inc.
(CLMX)27

3/7/00
10/31

6S

$8-$10

24.2

Prudential Vector Healthcare; ING Barings LLC; Dain Rauscher Wessels

$54

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available, applicable or reported.

TSE = Toronto Stock Exchange

1 AgraQuest filed a registration statement with the SEC to raise $75M in an IPO.

2 APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

3 BioNumerik filed for a $50M IPO. The number of shares to be offered, the price range, and the number of shares outstanding were not disclosed.

4 CombiMatrix did not disclose any further details.

5 diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

6 Northwest filed for an IPO expected to raise $48.3M in August. It amended the filing in October to raise $35M. The underwriter has an overallotment option for an additional 525,000 shares.

7 Ribapharm's IPO originally was proposed in June 2000. The company amended its prospectus on May 15. The value, $252M, is based on the offering of 18M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares.

8 Xcyte did not disclose any further details.

9 ZymoGenetics filed to raise $180M in an IPO.

10 Ariad's offering value is based on the proposed maximum offering share price of $4.79.

11 Cell Pathways filed a shelf registration for the sale of $25M in common stock.

12 Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

13 The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01.

14 Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration.

15 Exelixis filed a shelf registration to sell up to $150M in common stock.

16 Genaissance filed a shelf registration to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

17 ICOS filed a shelf registration statement for up to $300M.

18 InSite filed a shelf registration to sell $40M in stock

19 Labopharm's underwriters have an option to purchase an additional 780,000 shares to cover overallotments.

20 Matrix filed a shelf registration covering up to $30M in securities.

21 Microcide filed a shelf registration for the sale of up to $35M in securities. (Microcide is now Essential Therapeutics Inc. , formed through its merger with The Althexis Company Inc.)

22 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. The company amended its prospectus April 19. In May, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M.

23 Tularik filed to sell up to $250M in common stock and debt securities.

24 Valentis filed to sell up to $45M worth of equity warrants, preferred and common stock through a shelf registration statement.

25 ViroPharma filed a universal shelf registration for $300M in mixed securities.

26 Vysis registered to sell 4M shares, 3M of which will be sold by shareholder BP plc. The value of the offering, $26M, is based on the closing stock price of $25.96 on Aug. 7. The underwriters have an overallotment option for 600,000 shares. (Vysis is now being purchased by Abbott Laboratories.)

27 Cellomics postponed its initial public offering proposed in December 2000. It withdrew it in October, citing market conditions.